Global Genital Herpes Treatment Market

Genital Herpes Treatment Comprehensive Study by Type (Acyclovir, Valacyclovir, Famciclovir), Application (HSV-1, HSV-2), Route of Administration (Oral, Topical, Injectable), Distribution Channel (Hospital Pharmacies, General Pharmacies, Drug stores, Online) Players and Region - Global Market Outlook to 2030

Genital Herpes Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Genital Herpes Treatment
General herpes is categorized as a sexually transmitted disease/infection (STI) which is caused by herpes simplex virus. The genital herpes treatment includes the use of drug types like Acyclovir that can treat herpes virus infections, including shingles. This medication does not cure herpes, but may prevent herpes sores or blisters. It is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR4.0%


The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Teva (Israel), Abbott Laboratories (United States), Sun Pharmaceutical Industries Ltd. (India), Mylan (United States), Pfizer (United States), GlaxoSmithKline (United Kingdom), Dr. Reddy's (India), Novartis (Switzerland), Bausch Health (Canada) and Ranbaxy Laboratories Ltd. (India) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Genital Herpes Treatment market by Type (Acyclovir, Valacyclovir and Famciclovir), Application (HSV-1 and HSV-2) and Region.



On the basis of geography, the market of Genital Herpes Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Genital Herpes Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Genital Herpes Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing awareness about genital herps treatment and rapidly developing hospital network

Market Growth Drivers:
Increasing No Of Sexually Transmitted Disease Population and Emerging New Disorders Like Zika Virus

Challenges:
Research And Studies Not Getting Results For Enhancement In Treatments and Life-Threatening And High-Cost Associated With Treatment

Restraints:
Some Disorder Are Highly Incurable And Only Can Be Managed and Symptoms And Damages Ignored Due To Social Fear

Opportunities:
Growing Awareness About Treatment Of Sexually Transmitted Disease By Various Organisation And Social Platforms

Market Leaders and their expansionary development strategies
In October 2023, Atai Life Sciences announced a collaboration with Inbios to develop and commercialize Inbios' oral antiviral drug candidate, ABI-429, for the treatment of HSV-2.
In December 2023, Evgen Pharma received marketing authorization in Europe for its topical antiviral gel, EVO-002, for the treatment of recurrent HSV-2 outbreaks.
On 23rd May 2019, US FDA cleared the first diagnostic tests for extra-genital testing for Chlamydia and gonorrhea. U.S. Food and Drug Administration has recently cleared marketing for its first diagnostic test which will detect the bacteria of Chlamydia trachomatis and Neisseria gonorrhoeae which is the reason for transmitting STDs.

Key Target Audience
Raw material suppliers, Distributors/traders/wholesalers/suppliers, Regulatory bodies, including government agencies and NGO, Commercial research & development (R&D) institutions, Importers and exporters, Government organizations, research organizations, and consulting firms, Trade associations and industry bodies and End-use industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Acyclovir
  • Valacyclovir
  • Famciclovir
By Application
  • HSV-1
  • HSV-2
By Route of Administration
  • Oral
  • Topical
  • Injectable

By Distribution Channel
  • Hospital Pharmacies
  • General Pharmacies
  • Drug stores
  • Online

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing No Of Sexually Transmitted Disease Population
      • 3.2.2. Emerging New Disorders Like Zika Virus
    • 3.3. Market Challenges
      • 3.3.1. Research And Studies Not Getting Results For Enhancement In Treatments
      • 3.3.2. Life-Threatening And High-Cost Associated With Treatment
    • 3.4. Market Trends
      • 3.4.1. Increasing awareness about genital herps treatment and rapidly developing hospital network
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Genital Herpes Treatment, by Type, Application, Route of Administration, Distribution Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Genital Herpes Treatment (Value)
      • 5.2.1. Global Genital Herpes Treatment by: Type (Value)
        • 5.2.1.1. Acyclovir
        • 5.2.1.2. Valacyclovir
        • 5.2.1.3. Famciclovir
      • 5.2.2. Global Genital Herpes Treatment by: Application (Value)
        • 5.2.2.1. HSV-1
        • 5.2.2.2. HSV-2
      • 5.2.3. Global Genital Herpes Treatment by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Topical
        • 5.2.3.3. Injectable
      • 5.2.4. Global Genital Herpes Treatment by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. General Pharmacies
        • 5.2.4.3. Drug stores
        • 5.2.4.4. Online
      • 5.2.5. Global Genital Herpes Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Genital Herpes Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Dr. Reddy's (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bausch Health (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ranbaxy Laboratories Ltd. (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Genital Herpes Treatment Sale, by Type, Application, Route of Administration, Distribution Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Genital Herpes Treatment (Value)
      • 7.2.1. Global Genital Herpes Treatment by: Type (Value)
        • 7.2.1.1. Acyclovir
        • 7.2.1.2. Valacyclovir
        • 7.2.1.3. Famciclovir
      • 7.2.2. Global Genital Herpes Treatment by: Application (Value)
        • 7.2.2.1. HSV-1
        • 7.2.2.2. HSV-2
      • 7.2.3. Global Genital Herpes Treatment by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Topical
        • 7.2.3.3. Injectable
      • 7.2.4. Global Genital Herpes Treatment by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. General Pharmacies
        • 7.2.4.3. Drug stores
        • 7.2.4.4. Online
      • 7.2.5. Global Genital Herpes Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Genital Herpes Treatment: by Type(USD Million)
  • Table 2. Genital Herpes Treatment Acyclovir , by Region USD Million (2018-2023)
  • Table 3. Genital Herpes Treatment Valacyclovir , by Region USD Million (2018-2023)
  • Table 4. Genital Herpes Treatment Famciclovir , by Region USD Million (2018-2023)
  • Table 5. Genital Herpes Treatment: by Application(USD Million)
  • Table 6. Genital Herpes Treatment HSV-1 , by Region USD Million (2018-2023)
  • Table 7. Genital Herpes Treatment HSV-2 , by Region USD Million (2018-2023)
  • Table 8. Genital Herpes Treatment: by Route of Administration(USD Million)
  • Table 9. Genital Herpes Treatment Oral , by Region USD Million (2018-2023)
  • Table 10. Genital Herpes Treatment Topical , by Region USD Million (2018-2023)
  • Table 11. Genital Herpes Treatment Injectable , by Region USD Million (2018-2023)
  • Table 12. Genital Herpes Treatment: by Distribution Channel(USD Million)
  • Table 13. Genital Herpes Treatment Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Genital Herpes Treatment General Pharmacies , by Region USD Million (2018-2023)
  • Table 15. Genital Herpes Treatment Drug stores , by Region USD Million (2018-2023)
  • Table 16. Genital Herpes Treatment Online , by Region USD Million (2018-2023)
  • Table 17. South America Genital Herpes Treatment, by Country USD Million (2018-2023)
  • Table 18. South America Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 19. South America Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 20. South America Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 21. South America Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 22. Brazil Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 23. Brazil Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 24. Brazil Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 25. Brazil Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 26. Argentina Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 27. Argentina Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 28. Argentina Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 29. Argentina Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 30. Rest of South America Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 32. Rest of South America Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 33. Rest of South America Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 34. Asia Pacific Genital Herpes Treatment, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 37. Asia Pacific Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 38. Asia Pacific Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 39. China Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 40. China Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 41. China Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 42. China Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 43. Japan Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 44. Japan Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 45. Japan Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 46. Japan Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 47. India Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 48. India Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 49. India Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 50. India Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 51. South Korea Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 52. South Korea Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 53. South Korea Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 54. South Korea Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 55. Taiwan Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 56. Taiwan Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 57. Taiwan Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 58. Taiwan Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 59. Australia Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 60. Australia Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 61. Australia Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 62. Australia Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 67. Europe Genital Herpes Treatment, by Country USD Million (2018-2023)
  • Table 68. Europe Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 69. Europe Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 70. Europe Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 71. Europe Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 72. Germany Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 73. Germany Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 74. Germany Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 75. Germany Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 76. France Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 77. France Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 78. France Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 79. France Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 80. Italy Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 81. Italy Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 82. Italy Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 83. Italy Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 84. United Kingdom Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 86. United Kingdom Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 87. United Kingdom Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 88. Netherlands Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 89. Netherlands Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 90. Netherlands Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 91. Netherlands Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 92. Rest of Europe Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 94. Rest of Europe Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 95. Rest of Europe Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 96. MEA Genital Herpes Treatment, by Country USD Million (2018-2023)
  • Table 97. MEA Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 98. MEA Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 99. MEA Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 100. MEA Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 101. Middle East Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 102. Middle East Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 103. Middle East Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 104. Middle East Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 105. Africa Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 106. Africa Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 107. Africa Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 108. Africa Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 109. North America Genital Herpes Treatment, by Country USD Million (2018-2023)
  • Table 110. North America Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 111. North America Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 112. North America Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 113. North America Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 114. United States Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 115. United States Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 116. United States Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 117. United States Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 118. Canada Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 119. Canada Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 120. Canada Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 121. Canada Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 122. Mexico Genital Herpes Treatment, by Type USD Million (2018-2023)
  • Table 123. Mexico Genital Herpes Treatment, by Application USD Million (2018-2023)
  • Table 124. Mexico Genital Herpes Treatment, by Route of Administration USD Million (2018-2023)
  • Table 125. Mexico Genital Herpes Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Genital Herpes Treatment: by Type(USD Million)
  • Table 137. Genital Herpes Treatment Acyclovir , by Region USD Million (2025-2030)
  • Table 138. Genital Herpes Treatment Valacyclovir , by Region USD Million (2025-2030)
  • Table 139. Genital Herpes Treatment Famciclovir , by Region USD Million (2025-2030)
  • Table 140. Genital Herpes Treatment: by Application(USD Million)
  • Table 141. Genital Herpes Treatment HSV-1 , by Region USD Million (2025-2030)
  • Table 142. Genital Herpes Treatment HSV-2 , by Region USD Million (2025-2030)
  • Table 143. Genital Herpes Treatment: by Route of Administration(USD Million)
  • Table 144. Genital Herpes Treatment Oral , by Region USD Million (2025-2030)
  • Table 145. Genital Herpes Treatment Topical , by Region USD Million (2025-2030)
  • Table 146. Genital Herpes Treatment Injectable , by Region USD Million (2025-2030)
  • Table 147. Genital Herpes Treatment: by Distribution Channel(USD Million)
  • Table 148. Genital Herpes Treatment Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 149. Genital Herpes Treatment General Pharmacies , by Region USD Million (2025-2030)
  • Table 150. Genital Herpes Treatment Drug stores , by Region USD Million (2025-2030)
  • Table 151. Genital Herpes Treatment Online , by Region USD Million (2025-2030)
  • Table 152. South America Genital Herpes Treatment, by Country USD Million (2025-2030)
  • Table 153. South America Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 154. South America Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 155. South America Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 156. South America Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 157. Brazil Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 158. Brazil Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 159. Brazil Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 160. Brazil Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 161. Argentina Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 162. Argentina Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 163. Argentina Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 164. Argentina Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 165. Rest of South America Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 166. Rest of South America Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 167. Rest of South America Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 168. Rest of South America Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 169. Asia Pacific Genital Herpes Treatment, by Country USD Million (2025-2030)
  • Table 170. Asia Pacific Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 171. Asia Pacific Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 172. Asia Pacific Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 173. Asia Pacific Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 174. China Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 175. China Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 176. China Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 177. China Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 178. Japan Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 179. Japan Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 180. Japan Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 181. Japan Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 182. India Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 183. India Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 184. India Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 185. India Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 186. South Korea Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 187. South Korea Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 188. South Korea Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 189. South Korea Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 190. Taiwan Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 191. Taiwan Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 192. Taiwan Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 193. Taiwan Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 194. Australia Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 195. Australia Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 196. Australia Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 197. Australia Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 202. Europe Genital Herpes Treatment, by Country USD Million (2025-2030)
  • Table 203. Europe Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 204. Europe Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 205. Europe Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 206. Europe Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 207. Germany Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 208. Germany Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 209. Germany Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 210. Germany Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 211. France Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 212. France Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 213. France Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 214. France Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 215. Italy Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 216. Italy Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 217. Italy Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 218. Italy Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 219. United Kingdom Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 220. United Kingdom Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 221. United Kingdom Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 222. United Kingdom Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 223. Netherlands Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 224. Netherlands Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 225. Netherlands Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 226. Netherlands Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 227. Rest of Europe Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 228. Rest of Europe Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 229. Rest of Europe Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 230. Rest of Europe Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 231. MEA Genital Herpes Treatment, by Country USD Million (2025-2030)
  • Table 232. MEA Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 233. MEA Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 234. MEA Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 235. MEA Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 236. Middle East Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 237. Middle East Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 238. Middle East Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 239. Middle East Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 240. Africa Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 241. Africa Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 242. Africa Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 243. Africa Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 244. North America Genital Herpes Treatment, by Country USD Million (2025-2030)
  • Table 245. North America Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 246. North America Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 247. North America Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 248. North America Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 249. United States Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 250. United States Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 251. United States Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 252. United States Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 253. Canada Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 254. Canada Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 255. Canada Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 256. Canada Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 257. Mexico Genital Herpes Treatment, by Type USD Million (2025-2030)
  • Table 258. Mexico Genital Herpes Treatment, by Application USD Million (2025-2030)
  • Table 259. Mexico Genital Herpes Treatment, by Route of Administration USD Million (2025-2030)
  • Table 260. Mexico Genital Herpes Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Genital Herpes Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Genital Herpes Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Genital Herpes Treatment: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Genital Herpes Treatment: by Distribution Channel USD Million (2018-2023)
  • Figure 8. South America Genital Herpes Treatment Share (%), by Country
  • Figure 9. Asia Pacific Genital Herpes Treatment Share (%), by Country
  • Figure 10. Europe Genital Herpes Treatment Share (%), by Country
  • Figure 11. MEA Genital Herpes Treatment Share (%), by Country
  • Figure 12. North America Genital Herpes Treatment Share (%), by Country
  • Figure 13. Global Genital Herpes Treatment share by Players 2023 (%)
  • Figure 14. Global Genital Herpes Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Genital Herpes Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 18. Teva (Israel) Revenue: by Geography 2023
  • Figure 19. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 20. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 21. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 22. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2023
  • Figure 23. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 24. Mylan (United States) Revenue: by Geography 2023
  • Figure 25. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer (United States) Revenue: by Geography 2023
  • Figure 27. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 29. Dr. Reddy's (India) Revenue, Net Income and Gross profit
  • Figure 30. Dr. Reddy's (India) Revenue: by Geography 2023
  • Figure 31. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 33. Bausch Health (Canada) Revenue, Net Income and Gross profit
  • Figure 34. Bausch Health (Canada) Revenue: by Geography 2023
  • Figure 35. Ranbaxy Laboratories Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 36. Ranbaxy Laboratories Ltd. (India) Revenue: by Geography 2023
  • Figure 37. Global Genital Herpes Treatment: by Type USD Million (2025-2030)
  • Figure 38. Global Genital Herpes Treatment: by Application USD Million (2025-2030)
  • Figure 39. Global Genital Herpes Treatment: by Route of Administration USD Million (2025-2030)
  • Figure 40. Global Genital Herpes Treatment: by Distribution Channel USD Million (2025-2030)
  • Figure 41. South America Genital Herpes Treatment Share (%), by Country
  • Figure 42. Asia Pacific Genital Herpes Treatment Share (%), by Country
  • Figure 43. Europe Genital Herpes Treatment Share (%), by Country
  • Figure 44. MEA Genital Herpes Treatment Share (%), by Country
  • Figure 45. North America Genital Herpes Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Teva (Israel)
  • Abbott Laboratories (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Mylan (United States)
  • Pfizer (United States)
  • GlaxoSmithKline (United Kingdom)
  • Dr. Reddy's (India)
  • Novartis (Switzerland)
  • Bausch Health (Canada)
  • Ranbaxy Laboratories Ltd. (India)
Select User Access Type

Key Highlights of Report


Feb 2024 217 Pages 78 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Genital Herpes Treatment Market Quantitative research analysis
Global Genital Herpes Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Teva (Israel), Abbott Laboratories (United States), Sun Pharmaceutical Industries Ltd. (India), Mylan (United States), Pfizer (United States), GlaxoSmithKline (United Kingdom), Dr. Reddy's (India), Novartis (Switzerland), Bausch Health (Canada) and Ranbaxy Laboratories Ltd. (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing awareness about genital herps treatment and rapidly developing hospital network" is seen as one of major influencing trends for Genital Herpes Treatment Market during projected period 2023-2030.
The Genital Herpes Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Genital Herpes Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Adult Diaper Rash Cream Comprehensive Study by Application (Hospitals and Clinics, Personal Care, Other), Rash (Irritant Dermatitis, Candida Dermatitis, Allergic Dermatitis, Bacterial Dermatitis), Di...
$ 3450
Pediatric Nutrition Ingredients Comprehensive Study by Type (Proteins, Fats and Oils, Carbohydrates, Vitamins and Minerals, Others), Form (Powder, Liquid) Players and Region - Global Market Outlook t...
$ 3500
Everolimus Tablet Comprehensive Study by Type (2.5 mg Tablets, 5 mg Tablets, 7.5 mg Tablets, 10 mg Tablets), Application (Oncology, Organ transplant, Gastrointestinal, Others), Distribution Channel (...
$ 3450
Stomach Cancer Drugs Comprehensive Study by Type (Adenocarcinomas, Gastrointestinal Stromal Tumors, Neuroendocrine Tumors, Lymphomas, Carcinoid Tumors, Other Cancers), Drug Type (Programmed Cell Deat...
$ 3800
Cartilage Degeneration Comprehensive Study by Type (Fibrocartilage, Hyaline Cartilage, Others), Application (Knee, Spine, Ankle, Hip, Others), Treatment Modality (Cell-based, Non-Cell Based), Treatme...
$ 3800
Hypodontia Treatment Comprehensive Study by Type (Restorative Dentistry, Orthodontics, Oral Surgery, Others), Application (Hospitals, Dental Clinics, Others) Players and Region - Global Market Outloo...
$ 3500